Gennex Laboratories Share Price Today | Stock Price & Gennex Laboratories Share Screener
As of October 5, 2026, the live Gennex Laboratories share price (BSE: GENNEX) is ₹9.90, up 1.02% from the previous close, with shares trading between ₹9.76 and ₹10.25 in today's trading session, and a 52-week range of ₹7.13–₹17.02. Check GENNEX yearly price range for the annual price range and momentum. Use the Gennex Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gennex Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹42 and net income of ₹5, with EBITDA of ₹6, an operating margin of 11.0% and a profit margin of 11.9%.
Gennex Laboratories Share Price Chart
Track the current stock price of Gennex Laboratories with an interactive chart. Analyse GENNEX share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gennex Laboratories stock quote in one place.
The quote of ₹9.90 sits between the 52-week low of ₹7.13 and the 52-week high of ₹17.02, and the latest session moved 1.02% from the previous close.
Gennex Laboratories Company Profile - Fundamental Screener
Screen Gennex Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GENNEX shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE509C01026.
Company Details
Classification
Identifiers and Leadership
Gennex Laboratories Balance Sheet Screener
Screen GENNEX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹349, up from ₹256 in 2025.
Latest statistics put total assets at ₹349 and shareholder funds at ₹233, with a leverage ratio of 0.11.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 349 | 256 | 230 | 132 | 68 | 59 | 57 | 52 | 51 | 49 |
| Current Assets | 265 | 181 | 162 | 49 | 47 | 38 | 35 | 29 | 28 | 26 |
| Fixed Assets | 61 | 60 | 56 | 74 | 14 | 14 | 15 | 16 | 16 | 16 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 43 | 17 | 13 | 16 | 0 | 0 | 0 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 233 | 195 | 177 | 87 | 44 | 40 | 36 | 34 | 32 | 31 |
| Share Capital | 24 | 23 | 23 | 18 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 198 | 158 | 142 | 62 | 31 | 27 | 23 | 21 | 19 | 18 |
Gennex Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Gennex Laboratories income statement and profit fundamentals. Analyze GENNEX quarterly results. Gennex Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹42 and net profit was ₹5, equal to earnings per unit of ₹0.19, at an operating margin of 11%.
In that period expenses were ₹36, interest cost ₹1 and tax ₹0. The next period listed, 2026-Mar, shows revenue of ₹62 and net profit of ₹5.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 42 | 62 | 40 | 37 | 37 | 44 | 38 | 32 | 31 | 34 | 19 | 18 | 17 | 19 | 14 |
| Expenses | 36 | 55 | 35 | 32 | 29 | 39 | 33 | 26 | 24 | 29 | 17 | 12 | 11 | 17 | 13 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 6 | 7 | 6 | 6 | 7 | 6 | 5 | 6 | 7 | 4 | 3 | 5 | 5 | 1 | 1 |
| Operating Profit % | 11.00% | 9.00% | 14.00% | 15.00% | 15.00% | 5.00% | 13.00% | 18.00% | 15.00% | 13.00% | 13.00% | 29.00% | 31.00% | 7.00% | 8.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 5 | 5 | 7 | 6 | 6 | 4 | 6 | 6 | 6 | 5 | 4 | 4 | 4 | 3 | 2 |
| Tax | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Net Profit | 5 | 5 | 6 | 6 | 5 | 3 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 2 | 1 |
| EPS | 0.19 | 0.16 | 0.22 | 0.21 | 0.22 | 0.14 | 0.22 | 0.21 | 0.19 | 0.16 | 0.16 | 0.16 | 0.16 | 0.19 | 0.07 |
Gennex Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen GENNEX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹64, and net cash flow was an outflow of ₹3.
Over the same period, investing activities used ₹5 and financing activities provided ₹65.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -64 | -10 | -47 | 24 | 12 | -1 | -2 | 2 | 3 | 0 |
| Investing Activities | -5 | 3 | 19 | -38 | -3 | 0 | 0 | -1 | -1 | -1 |
Financing and Net Cash | ||||||||||
| Financing Activities | 65 | 2 | 74 | 21 | -2 | 2 | 0 | 1 | -2 | 1 |
| Net Cash Flow | -3 | -5 | 46 | 6 | 8 | 0 | -2 | 2 | 0 | 0 |
Gennex Laboratories Shareholding Pattern Screener
See Gennex Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Gennex Laboratories promoter holding and ownership changes for GENNEX on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 23.63%, foreign institutions 0.00%, domestic institutions 0.00% and the public 56.49%, spread across 82,886 shareholders.
The shareholder count was 82,886 in 2026-Jun, compared with 84,133 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jul | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 23.63% | 23.63% | 23.62% | 23.62% | 23.62% | 19.83% | 18.42% | 18.42% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 56.49% | 55.79% | 56.47% | 59.34% | 58.97% | 61.90% | 62.19% | 60.53% |
| Other Holding | 19.88% | 20.58% | 19.91% | 17.04% | 17.41% | 18.28% | 19.39% | 21.05% |
| Shareholder Count | 82,886 | 84,133 | 86,306 | 90,320 | 91,183 | 91,183 | 92,326 | 92,506 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gennex Laboratories. Gennex Laboratories dividend yield can be compared with peers and other stocks in the market.
Gennex Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Gennex Laboratories stock. Check GENNEX index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Gennex Laboratories Market Events Screener - Corporate Actions
Get Gennex Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gennex Laboratories stock events that may affect GENNEX share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Quarterly Result Announcement dated August 14, 2026 and Quarterly Result Announcement dated May 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -14.58% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 6.23% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 28.92% |
| 2026-05-12 | 2026-05-12 | Extraordinary General Meeting | NA | -2.64% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -1.68% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 1.36% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -0.44% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -4.23% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 5.19% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -6.70% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -5.88% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 27.26% |
| 2023-12-30 | 2023-12-30 | Extraordinary General Meeting | NA | 4.41% |
| 2022-07-21 | 2022-07-22 | Rights | 1:2 | 2.40% |
Gennex Laboratories Competitors Screener - Peer Stocks Comparison
Screen GENNEX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,010 | 35.84 | 61,674 | 12.69% | 11,565 | 33.78 |
| Divis Laboratories | 244,125 | 84.36 | 11,067 | 13.95% | 2,568 | 49.73 |
| Torrent Pharmaceuticals | 181,512 | 84.01 | 13,886 | 20.34% | 2,138 | 41.48 |
| Zydus Life Science | 113,616 | 24.88 | 27,658 | 17.64% | 5,026 | 46.18 |
| Cipla | 107,890 | 32.42 | 29,045 | 2.24% | 3,870 | 32.87 |
| Laurus Labs | 106,517 | 98.56 | 6,868 | 22.01% | 890 | 56.11 |
| Mankind Pharma | 102,394 | 50.48 | 14,636 | 14.85% | 1,938 | 55.53 |
| Dr Reddys Laboratories | 100,412 | 31.47 | 35,059 | 3.90% | 4,158 | 52.91 |
| Aurobindo Pharma | 96,370 | 25.97 | 34,145 | 5.56% | 3,503 | 49.89 |
| Lupin | 91,961 | 16.71 | 29,039 | 26.75% | 5,356 | 29.12 |
Gennex Laboratories Company Announcements - News & Reports Screener
Screen GENNEX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated October 2, 2026 and October 1, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-22 | Closure of Trading Window | - |
| 2026-09-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-08 | Approval Of Additional Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies Limited | - |
| 2026-09-08 | Reg. 34 (1) Annual Report. | - |
| 2026-09-04 | Intimation Of Book Closure For The Purpose Of 41St AGM Of Gennex Laboratories Limited | - |
| 2026-09-04 | Board Meeting Outcome for Meeting Held On September 04 2026 | - |
| 2026-08-27 | Board Meeting Intimation for For Fixing Date Time And Venue Of 41St AGM Of The Company | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Un-Audited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-14 | Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-07-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-29 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026. | - |
| 2026-07-17 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-23 | Closure of Trading Window | - |
| 2026-06-10 | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. | - |
| 2026-06-10 | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. | - |
| 2026-06-10 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹9.90, within a 52-week range of ₹7.13 to ₹17.02. The P/E ratio is 11.53 and the P/B ratio is 1.07, with earnings per unit of ₹0.87. Market capitalisation stands at ₹241.26 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.